Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

BACKGROUND: LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wan-Hong, Wang, Bai-Yan, Chen, Li-Juan, Fu, Wei-Jun, Xu, Jie, Liu, Jie, Jin, Shi-Wei, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Zhang, Hui, Bai, Ju, Xu, Yan, Zhu, Han, Du, Juan, Jiang, Hua, Fan, Xiao-Hu, Li, Jian-Yong, Hou, Jian, Chen, Zhu, Zhang, Wang-Gang, Mi, Jian-Qing, Chen, Sai-Juan, He, Ai-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261106/
https://www.ncbi.nlm.nih.gov/pubmed/35794616
http://dx.doi.org/10.1186/s13045-022-01301-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261106/
https://www.ncbi.nlm.nih.gov/pubmed/35794616
http://dx.doi.org/10.1186/s13045-022-01301-8

Ejemplares similares